Selected Publications
Zhu Z, Chen X, Guo A, Manzano T, Walsh PJ, Wills KM, Halliburton R, Radko-Juettner S, Carter RD, Partridge JF, Green DR, Zhang J, Roberts CWM. Mitotic bookmarking by SWI/SNF subunits. Nature May 24;618:180-187, 2023.
Dharia NV, Kugener G, Guenther LM, Malone CF, Durbin AD, Hong AL, Howard TP, Bandopadhayay P, Wechsler CS, Fung I, Warren AC, Dempster JM, Krill-burger JM, Paolella BR, Moh P, Jha N, Tang A, Montgomery P, Boehm JS, Hahn WC, Roberts CWM, McFarland JM, Tsherniak A, Golub TR, Vazquez F, Stegmaier K. A First-Generation Pediatric Cancer Dependency Map. Nature Genetics 53:529-538, 2021.
Howard TP, Roberts CWM. Partitioning of Chemotherapeutics into Nuclear Condensates-Opening the Door to New Approaches for Drug Development. Mol Cell Aug 20;79(4):544-545, 2020. doi: 10.1016/j.molcel.2020.07.029. PMID: 32822580
Howard TP, Oberlick EM, Rees MG, Arnoff TE, Pham MT, Brenan L, DoCarmo M, Hong AL, Kugener G, Chou HC, Drosos Y, Mathias KM, Ramos P, Seashore-Ludlow B, Giacomelli AO, Wang X, Freeman BB 3rd, Blankenship K, Hoffmann L, Tiv HL, Gokhale PC, Johannessen CM, Stewart EA, Schreiber SL, Hahn WC, Roberts CWM. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clin Cancer Res Sep 15;26(18):4995-5006, 2020. doi: 10.1158/1078-0432.CCR-19-2717. Epub 2020 Jul 6. PMID: 32631955
Mittal P, Roberts CWM. The SWI/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol Jul;17(7):435-448, 2020. doi: 10.1038/s41571-020-0357-3. Epub 2020 Apr 17. PMID: 32303701 Review.
Oberlick EM, Rees MG, Seashore-Ludlow B, Vazquez F, Nelson G, Dharia NV, Weir BA, Tsherniak A, Ghandi M, Krill-Burger JM, Meyers RM, Wang X, Montgomery P, Root DE, Bieber JM, Radko S, Cheah JH, Hon SY, Shamji AF, Clemons PA, Park PJ, Dyer MA, Golub TR, Stegmaier K, Hahn WC, Stewart EA, Schreiber SL, Roberts CWM. Small-molecule and CRISPR screening converge to reveal RTK dependencies in pediatric rhabdoid tumors. Cell Reports 28(9):2331-2344, 2019.
Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Research 79:2404-2414, 2019.
Wang W, Wang S, Troisi E, Howard T, Haswell J, Wolf B, Hawk W, Ramos P, Oberlick E, Tzvetkov E, Vazquez F, Hahn W, Park P, Roberts CWM. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. Nature Communications 10:1881, 2019.
Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, Ward A, McSteen B, Labella KM, Keskula P, Tracy A, Connor C, Clinton CM, Church AJ, Crompton BD, Janeway KA, Van Hare B, Sandak D, Gjoerup O, Bandopadhayay P, Clemons PA, Schreiber SL, Root DE, Gokhale PC, Chi SN, Mullen EA, Roberts CWM, Kadoch C, Beroukhim R, Ligon KL, Boehm JS, Hahn WC. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife 8, 2019. pii: e44161. doi: 10.7554/eLife.44161
Erkek S, Johann P, Finetti M, Drosos Y, Chou HC, Zapatka M, Sturm D, Jones D, Korshunov A, Rhyzova M, Wolf S, Mallm JP, Beck K, Witt O, Kulozik A, Frühwald M, Northcott P, Korbel J, Lichter P, Eils R, Gajjar A, Roberts CWM, Williamson D, Hasselblatt M, Chavez L, Pfister S, Kool M. Comprehensive analysis of chromatin states in atypical teratoid rhabdoid tumors identifies diverging roles for SWI/SNF and Polycomb in the regulation of different sets. Cancer Cell 35:95-110, 2019.
Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, and Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35:204-220, 2019.
Witwicki R, Ekram M, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan H, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers W, Jagani Z, Hogarty M, Roberts CWM, Brown M, Stegmaier K, Long H, Shivdasani R, Pellman D, Polyak K. TRPS1 is a lineage-specific transcriptional dependency in breast cancer. Cell Reports 25:1255-1267, 2018.
Giacomelli A, Yang X, Lintner R, Duby M, Kim J, Howard T, Takeda D, LY S, McFarland J, Kim E, Gannon H, Hurhula B, Sharpe T, Goodale A, Fitchman B, Steelman S, Vazquez F, Tsherniak A, Aguirre A, Doench J, Piccioni F, Roberts CWM, Meyerson M, Getz G, Johannessen C, Root D, Hahn W. Mutational processes shape the landscape of TP53 mutations in human cancer. Nature Genetics 50:1381-1387, 2018.
Kuwahara Y, Kennedy L, Karnezis A, Mora-Blanco EL, Rogers A, Fletcher C, Huntsman D, Roberts CWM, Rathmell WK and Weissman B. High Frequency of Ovarian Cyst Development in VhL2B/+;Snf5+/-Mice. American Journal of Pathology 188:1510-1516, 2018.
Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pante S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burge JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CWM, Hahn WC, Weiss WA, Thiele CJ, and Stegmaier K. CRISPR-Cas9 Screen Reveals a MYCN-amplified Neuroblastoma Dependency on EZH2. Journal of Clinical Investigation 128:446-462, 2018.
Mathur R and Roberts CWM. SWI/SNF (BAF) Complexes: Guardians of the Epigenome. Annual Review of Cancer Biology 2:413-427, 2018.
Vierbuchen T, Ling E, Cowley CJ, Couch CH, Wang X, Harmin DA, Roberts CW, and Greenberg ME. The pioneer factors Fos/Jun recruit mSWI/SNF to specify and activate late-response gene enhancers. Molecular Cell 68:1067-1082, 2017.
Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, deCubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker, CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Establishing standards in renal medullary carcinoma (RMC): proceedings of the first annual meeting of the MRC working group. Journal of Oncology Practice 13:414-421, 2017.
Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, Emde AK, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA, and Kentsis A. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics 49:1005-1014, 2017.
Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong L, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P , Jiang S, Garvey J, Liu CG , Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood L, Sgambato A, Agaimy A, Maitra A, Roberts CWM, Wang H , Viale A, DePinho RA, Draetta GF and Chin L . Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542:362-366, 2017.
Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, Haswell JR, Park PJ, Roberts CW. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nat Commun Mar 6;8:14648, 2017. doi: 10.1038/ncomms14648. PMID: 28262751
Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet Feb;49(2):296-302, 2017. doi: 10.1038/ng.3744. Epub 2016 Dec 12. PMID: 27941798
Wang X, Lee RS, Alver BH, Haswell JR, Wang S, Mieczkowski J, Drier Y, Gillespie SM, Archer TC, Wu JN, Tzvetkov EP, Troisi EC, Pomeroy SL, Biegel JA, Tolstorukov MY, Bernstein BE, Park PJ, Roberts CW. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet Feb;49(2):289-295, 2017. doi: 10.1038/ng.3746. Epub 2016 Dec 12. PMID: 27941797
Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, Kryukov GV, Clemons PA, Tsherniak A, Vazquez F, Crompton BD, Shamji AF, Rodriguez-Galindo C, Janeway KA, Roberts CW, Stegmaier K, van Hummelen P, Cima MJ, Langer RS, Garraway LA, Schreiber SL, Root DE, Hahn WC, Boehm JS. Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications 7:11987, 2016.
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, Lee Y, Goodale A, Cherniack AD, Oh C, Kryukov G, Cowley GS, Garraway LA, Stegmaier K, Roberts CW, Golub TR, Meyerson M, Root DE, Tsherniak A, Hahn WC. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery 6:914-29, 2016.
Fruhwald MC, Biegel JA, Roberts CWM and Chi SN. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol 18:764-78, 2016.
Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CWM, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol Jan 28, 2016. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print]
Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nature Medicine 22:128-34, 2016.
Kim KH, Woojin K, Howard TP, Vazquez F, Tsherniak A, Wu JN, Wang W, Haswell JR, Walensky LD, Hahn WC, Orkin SH, Roberts CWM. SWI/SNF-mutant cancers depend upon catalytic and non-catalytic activity of EZH2. Nature Medicine Dec;21(12):1491-6, 2015.
Yin J, Leavenworth JW, Li Y, Luo Q, Xie H, Liu X, Huan S, Yan H, Fu Z, Zhang LY, Zhang LT, Hao J, Wu X, Deng X, Roberts CWM, Orkin SH, Cantor H, Wang X. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. PNAS Dec. 14, 2015. [Epub ahead of print]
Fahiminya S, Witkowski L, Nadaf J, Carrot-Zhang J, Goudie C, Hasselblatt M, Lee RS, Gayden T, Roberts CWM, Biegel JA, Jabado N, Majewski J, Foulkes WD. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. Oncotarget Dec 4, 2015. [Epub ahead of print]
Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CWM, Siu L, Snyder A, Stower H, Swanton C, Verhaak RG, Zenklusen JC, Zuber J, Zucman-Rossi J. Toward understanding and exploiting tumor heterogeneity. Nature Medicine 21(8):846-853, 2015. PMID: 26248267.
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Tailor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CWM, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA Dec 23;111:E5564-73, 2014. PMID: 25512523 PMCID: PMC4280630
Pugh TJ, Yu W, Yang J, Ambrogio L, Field A, Carter SL, Cibulskis K, Giannikopoulos P, Kiezun A, Kim J, McKenna A, Nickerson E, Getz G, Hoffner S, Messinger YH, Dehner LP, Roberts CWM, Rodriguez-Galindo C, Williams GM, Rossi CT, Meyerson M, Hill DA. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two-hit DICER1 loss resulting in retention of 5p-derived miRNA hairpins. Oncogene Nov 6;33:5295-302, 2014. PMID: 24909177 PMCID: PMC4224628
Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CWM. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature Medicine 20(3):251-4, 2014. PMID: 24562383 PMCID: PMC3954704
Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K, Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA, Keen N, McLaughlin ME, Mickanin C, Roberts CWM, Stegmeier F, Jagani Z. A functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proceedings of the National Academy of Sciences USA 111(8): 3128-33, 2014. PMID: 24520176 PMCID: PMC3939885
Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC, Roberts CWM. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Molecular and Cellular Biology 34(6):1136-44, 2014. PMID: 24421395 PMCID: PMC3958034
Helming KC, Wang X, Roberts CWM. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26: 309-317, 2014. PMID: 25203320 PMCID: PMC4159614
Kim KH, Roberts CWM. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genetics 207:365-372, 2014. PMID: 24853101 PMCID: PMC4195815
Wang X, Haswell JR, Roberts CWM. SWI/SNF (BAF) complexes are frequently mutated in cancer: mechanisms and potential therapeutic insights. Clinical Cancer Research 20: 21-7, 2014. PMID: 24122795 PMCID: PMC3947303
Mora-Blanco EL, Mishina Y, Tillman EJ, Cho Y-J, Thom CS, Pomeroy SL, Shao W, Roberts CWM. Activation of b-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene Feb 13;33:933-38, 2014. PMID: 23435428
Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, Hofmann F, Roberts CWM, Graus Porta D. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One 8(10):e77652, 2013. PMID: 24204904 PMCID: PMC3813701
Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson BG, Park PJ, Roberts CWM. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proceedings of the National Academy of Sciences 110: 10165-70, 2013. PMID: 23723349 PMCID: PMC3690861
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Jing R, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass A, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 499:214-8, 2013. PMID: 23770567 PMCID: PMC3919509
Kuwahara Y, Mora-Blanco EL, Banine F, Rogers A, Fletcher C, Sherman L, Roberts CWM, Weissman B. Establishment and Characterization of MRT Cell Lines from Genetically Engineered Mouse Models and the Influence of Genetic Background on Their Development. International Journal of Cancer 132:2767-77, 2013. PMID: 23197309 PMCID: PMC3605221
Lu P, Roberts CWM. The SWI/SNF tumor suppressor complex: Regulation of promoter nucleosomes and beyond. Nucleus 4:374-378, 2013. PMID: 24145903 PMCID: PMC3899127
Lee RS, Roberts CWM. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer. Brain Pathology 23:200-5, 2013. PMID: 23432645
Wu JN, Roberts CWM. ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor? Cancer Discovery 3:35-43, 2013. PMID: 23208470 PMCID: PMC3546152
Kieran MW, Roberts CWM, Chi SN, Ligon KL, Rich BE, MacConaill LE, Garraway LA, and Biegel JA. Absence of Oncogenic Canonical Pathway Mutations in Aggressive Pediatric Rhabdoid Tumors. Pediatric Blood and Cancer 59:1155-7, 2012. PMID: 22997201 PMCID: PMC3538080
Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougne C, Lawrence MS, Auclair D, Mora J, Golub TR, Biegel JA, Getz G, Roberts CWM. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. Journal of Clinical Investigation 122:2983-2988, 2012. PMID: 22797305 PMCID: PMC3408754
McKenna ES, Tamayo P, Cho Y-J, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CWM. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle 11:1956-65, 2012. PMID: 22544318 PMCID: PMC3359122
Wang X, Werneck MBF, Wilson BG, Kim H-J, Kluk MJ, Thom CS, Wischhusen JW, Evans JA, Jesneck JL, Nguyen P, Sansam CG, Cantor H, Roberts CWM. T cell receptor dependent transformation of mature memory phenotype T cells in mice. Journal of Clinical Investigation 121:3834-3845, 2011. PMID: 21926465 PMCID: PMC3195451
Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PTL, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky S, Murtie J, Kelleher J, Warmuth M, Sellers WR, Roberts CWM*, Dorsch M* (*Co-corresponding senior authors and contributed equally). Loss of the Tumor Suppressor Snf5 Leads to Aberrant Activation of the Hedgehog-Gli Pathway.Nature Medicine 16:1374-6, 2010. PMID: 21076395 PMCID: PMC3859448
Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH, Roberts CWM.Epigenetic antagonism between Polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell Oct 19;18(4):316-28, 2010. PMID: 20951942 PMCID: PMC2957473
DelBove J, Kuwahara Y, Mora-Blanco EL, Godfrey V, Funkhouser WK, Fletcher CD, Van Dyke T, Roberts CW, Weissman BE. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice. Mol Carcinog Dec; 48(12):1139-48, 2009. PMID: 19676100 PMCID: PMC3527082
Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PTL, Roberts CWM. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent upon activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Research 69:8094-8101, 2009.PMID: 19789351 PMCID: PMC2763035
Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, Yaniv M, Muchardt C, Metzger D, Chambon P, Roberts CWM, Knudsen ES. SWI/SNF-Deficiency Results in Aberrant Chromatin Organization, Mitotic Failure, and Diminished Proliferative Capacity. Molecular Biology of the Cell20:3192-9, 2009. PMID: 19458193 PMCID: PMC2710832
Roberts CWM, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biology & Therapy8:412-416, 2009. PMID: 19305156 PMCID: PMC2709499
McKenna ES, Roberts CWM. Epigenetics and cancer without genomic instability. Cell Cycle 28:1-4, 2009. PMID: 19098432
Last update: June 2023